Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for Refractory CMV Infection After allo-HSCT
NCT02083731Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells in cytomegalovirus infection (CMV), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Complete Remission at 1 year. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02083731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083731.